485 related articles for article (PubMed ID: 17891838)
41. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
42. Surgical resection of a virilizing adrenal mass with extensive tumor thrombus.
Gahan J; Shirodkar SP; Gorin MA; Salerno TA; Ciancio G
Can J Urol; 2011 Jun; 18(3):5735-8. PubMed ID: 21703051
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant mitotane for adrenocortical cancer--working through uncertainty.
Terzolo M; Fassnacht M; Ciccone G; Allolio B; Berruti A
J Clin Endocrinol Metab; 2009 Jun; 94(6):1879-80. PubMed ID: 19494162
[No Abstract] [Full Text] [Related]
44. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
[TBL] [Abstract][Full Text] [Related]
45. Mitotane in adrenocortical carcinoma.
Vassilopoulou-Sellin R; Guinee VF
Br J Cancer; 1994 Oct; 70(4):779. PubMed ID: 7917941
[No Abstract] [Full Text] [Related]
46. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
47. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
Veytsman I; Nieman L; Fojo T
J Clin Oncol; 2009 Sep; 27(27):4619-29. PubMed ID: 19667279
[TBL] [Abstract][Full Text] [Related]
48. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
49. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
50. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
51. Rare adrenal tumors in children.
Mihai R
Semin Pediatr Surg; 2014 Apr; 23(2):71-5. PubMed ID: 24931351
[TBL] [Abstract][Full Text] [Related]
52. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?
Wierman ME
Lancet Oncol; 2024 May; 25(5):534-535. PubMed ID: 38608692
[No Abstract] [Full Text] [Related]
53. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
54. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
Kasperlik-Załuska AA; Migdalska BM; Zgliczyński S; Makowska AM
Cancer; 1995 May; 75(10):2587-91. PubMed ID: 7736405
[TBL] [Abstract][Full Text] [Related]
55. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
[TBL] [Abstract][Full Text] [Related]
56. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
57. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
58. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
59. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
60. [Features of clinical presentation of malignant adrenocortical tumor cortex metabolism over time].
Kvacheniuk AM
Lik Sprava; 2003 Dec; (8):52-4. PubMed ID: 14965007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]